Showing results (221-230 of 286) with videos related to

Sort By:
Pageof 29
Lung Cancer (Amsterdam, Netherlands)|June 13, 2026
Rechallenge with zongertinib after trastuzumab deruxtecan in HER2-mutant lung cancer: A case reportHayato Koba, Yuichi Tambo, Yuya Murase, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profilesKenji Ikuta, Seiji Yano, Van The Trung, et al.
International Journal of Clinical Oncology|May 17, 2024
Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET studyKaname Nosaki, Kiyotaka Yoh, Ryo Toyozawa, et al.
The American Journal of Pathology|March 19, 2013
Surfactant protein A suppresses lung cancer progression by regulating the polarization of tumor-associated macrophagesAtsushi Mitsuhashi, Hisatsugu Goto, Takuya Kuramoto, et al.
Nature Chemical Biology|May 19, 2019
Macrocyclic peptide-based inhibition and imaging of hepatocyte growth factorKatsuya Sakai, Toby Passioura, Hiroki Sato, et al.
Cancer Science|August 22, 2019
Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistanceKenji Kita, Koji Fukuda, Hiro Takahashi, et al.
Cancer Science|November 26, 2014
Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesotheliomaQi Li, Wei Wang, Yusuke Machino, et al.
Cancer Letters|September 17, 2021
Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancerKeiko Tanimura, Tadaaki Yamada, Mano Horinaka, et al.
Bioorganic & Medicinal Chemistry|March 8, 2024
Drug-drug conjugates of MEK and Akt inhibitors for RAS-mutant cancersHikaru Fujita, Sachiko Arai, Hiroshi Arakawa, et al.
Cancer Medicine|April 20, 2023
Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non-small-cell lung cancer with bone metastasisYohei Asano, Norio Yamamoto, Satoru Demura, et al.
Pageof 29